TOP TEN perturbations for 1267_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1267_at
Selected probe(set): 218764_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1267_at (218764_at) across 6673 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):5.9250402
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

AsPC-1 / BxPC-3

Relative Expression (log2-ratio):-4.885371
Number of Samples:3 / 3
Experimental AsPC-1
Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code:
Control BxPC-3
Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code:

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.9463263
Number of Samples:2 / 3
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).

stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)

Relative Expression (log2-ratio):-3.9043837
Number of Samples:2 / 2
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.8784618
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)

Relative Expression (log2-ratio):3.8285666
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted).

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.7248392
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):3.6906548
Number of Samples:17 / 5
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (MLL-rearranged) / T-ALL study 3

Relative Expression (log2-ratio):-3.5039663
Number of Samples:5 / 29
Experimental precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

A. fumigatus study 1 / uninfected immature dendritic cell sample

Relative Expression (log2-ratio):3.4006805
Number of Samples:2 / 2
Experimental A. fumigatus study 1
5 x 106 immature dendritic cells were cultivated together with 5 x 106 A. fumigatus germ tubes for 6h until isolation of total RNA.
Control uninfected immature dendritic cell sample
5 x 106 immature dendritic cells were cultivated without fungi.

Organism: Homo sapiens
Gene: 1267_at
Selected probe(set): 206099_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1267_at (206099_at) across 6673 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 2 (multifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.9846191
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-2.8836184
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-2.8192577
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Langerhans cell histiocytosis study 2 (unifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.7232666
Number of Samples:8 / 10
Experimental Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.3900146
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multisystem)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):2.3566713
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.

VTX-2337 study 1 / 3M-055 study 1

Relative Expression (log2-ratio):2.3490229
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control 3M-055 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):2.2883968
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

septic shock study 3 (D3; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-2.252677
Number of Samples:9 / 22
Experimental septic shock study 3 (D3; non-survivor)
Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D2; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-2.2361736
Number of Samples:8 / 22
Experimental septic shock study 3 (D2; non-survivor)
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.